BRPI0821474A2 - formulação farmacêutica líquida estável - Google Patents

formulação farmacêutica líquida estável

Info

Publication number
BRPI0821474A2
BRPI0821474A2 BRPI0821474A BRPI0821474A BRPI0821474A2 BR PI0821474 A2 BRPI0821474 A2 BR PI0821474A2 BR PI0821474 A BRPI0821474 A BR PI0821474A BR PI0821474 A BRPI0821474 A BR PI0821474A BR PI0821474 A2 BRPI0821474 A2 BR PI0821474A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
liquid pharmaceutical
stable liquid
stable
formulation
Prior art date
Application number
BRPI0821474A
Other languages
English (en)
Inventor
Schwarz Hans-Peter
Schnecker Kurt
Matthiessen Peter
Turecek Peter
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0821474(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of BRPI0821474A2 publication Critical patent/BRPI0821474A2/pt
Publication of BRPI0821474B1 publication Critical patent/BRPI0821474B1/pt
Publication of BRPI0821474B8 publication Critical patent/BRPI0821474B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BRPI0821474A 2007-12-28 2008-12-23 formulação farmacêutica líquida estável BRPI0821474B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1741807P 2007-12-28 2007-12-28
US61/017,418 2007-12-28
US1788107P 2007-12-31 2007-12-31
US61/017,881 2007-12-31
PCT/US2008/088201 WO2009086400A2 (en) 2007-12-28 2008-12-23 Recombinant vwf formulations

Publications (3)

Publication Number Publication Date
BRPI0821474A2 true BRPI0821474A2 (pt) 2017-05-09
BRPI0821474B1 BRPI0821474B1 (pt) 2021-03-30
BRPI0821474B8 BRPI0821474B8 (pt) 2021-05-25

Family

ID=40591819

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821474A BRPI0821474B8 (pt) 2007-12-28 2008-12-23 formulação farmacêutica líquida estável

Country Status (15)

Country Link
US (2) US20090192076A1 (pt)
EP (2) EP2244814B1 (pt)
JP (3) JP5784907B2 (pt)
KR (2) KR20160091434A (pt)
CN (2) CN105816858B (pt)
AR (1) AR069989A1 (pt)
AU (1) AU2008345135C1 (pt)
BR (1) BRPI0821474B8 (pt)
CA (1) CA2710762A1 (pt)
ES (1) ES2887187T3 (pt)
MX (1) MX2010007150A (pt)
NZ (1) NZ586383A (pt)
SG (2) SG187410A1 (pt)
TW (3) TWI515006B (pt)
WO (1) WO2009086400A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652782B2 (en) * 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2861667C (en) 2007-10-01 2017-06-13 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and methods of use
CN105816858B (zh) 2007-12-28 2024-10-18 武田药品工业株式会社 重组vwf配方
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
US20130034573A1 (en) * 2009-12-22 2013-02-07 Celldex Therapeutics, Inc. Vaccine compositions
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
ES2682249T3 (es) * 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
HRP20200007T1 (hr) 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
PL3158055T3 (pl) * 2014-06-13 2020-03-31 Csl Limited Ulepszone wytwarzanie rekombinowanego czynnika von Willebranda w bioreaktorze
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA3027998A1 (en) 2016-06-27 2018-01-04 Baxalta Incorporated Syringe stabilizer
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
CA3069295A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
CN107966567B (zh) * 2017-11-21 2018-12-18 浙江夸克生物科技有限公司 一种触珠蛋白测定试剂盒
CA3094644A1 (en) * 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
US12128090B2 (en) 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
US20230041240A1 (en) * 2020-01-30 2023-02-09 Leukocare Ag Reduction of Adsorption
ES3040184T3 (en) * 2020-03-18 2025-10-29 Gi Innovation Inc Fusion protein preparation comprising il-2 and cd80 proteins
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
CN119173446A (zh) 2022-03-08 2024-12-20 赤盾医疗有限公司 机器人药物制备系统中的流体转移站

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA7972A (en) * 1877-10-05 Edward M. Lowdon Improvements in lamps
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
US5900476A (en) * 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
ATE283864T1 (de) * 1991-06-20 2004-12-15 Aventis Behring L L C Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor
US5847086A (en) 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US20010046487A1 (en) * 1994-12-30 2001-11-29 Roser Bruce J. Methods for loading platelets, stabilizing platelets for dry storage and compositions obtained thereby
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
ATE305053T1 (de) 1996-07-19 2005-10-15 Univ Michigan Für den von willebrand faktor der hunde kodierende dna und verfahren zu ihrer verwendung
SE9604296D0 (sv) 1996-11-22 1996-11-22 Astra Ab New pharmaceutical formulation of polypeptides
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
FR2772381B1 (fr) 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
DE10043124A1 (de) * 2000-08-31 2002-03-14 Max Delbrueck Centrum Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase
EP1325127B1 (en) 2000-10-02 2009-03-11 Novo Nordisk Health Care AG Method for the production of vitamin k-dependent proteins
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
RU2362807C2 (ru) 2002-06-21 2009-07-27 Ново Нордиск Хелт Кэр Аг Конъюгат полипептида фактора vii, способ его получения, его применение и содержащая его фармацевтическая композиция
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
EP1587838B1 (en) * 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
RU2373953C2 (ru) * 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044421B4 (de) * 2004-09-14 2010-06-24 Biotest Ag Verfahren zur Trennung eines von Willebrand Faktors mit einer spezifischen VWF-Aktivität von wenigstens 50 E/mg VWF-Antigen von einem von Willebrand Faktor mit niedriger Aktivität und Verwendung von Hydroxylapatit dafür
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
GB0509443D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbents for factor VIII and von willebrand's factor
EP1899462B1 (en) * 2005-07-02 2011-03-09 Arecor Limited Stable aqueous systems comprising proteins
ES2390354T3 (es) * 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
HRP20120994T1 (hr) * 2006-02-07 2012-12-31 Shire Human Genetic Therapies, Inc. Stabilizirana smjesa glukocerebrozidaze
WO2008015187A1 (en) 2006-08-01 2008-02-07 Telefonaktiebolaget Lm Ericsson (Publ) User preferences in interactive personal television
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2008127654A2 (en) * 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
RU2469739C2 (ru) * 2007-04-26 2012-12-20 БАЙЕР ХЕЛСКЕА ЛЛСи Стабилизация жидких растворов рекомбинантного белка для хранения в замороженном состоянии
ES2392569T3 (es) 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
CN105816858B (zh) 2007-12-28 2024-10-18 武田药品工业株式会社 重组vwf配方
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
JP5643762B2 (ja) * 2008-10-15 2014-12-17 インターシア セラピューティクス，インコーポレイティド 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用
CA2740793A1 (en) * 2008-11-03 2010-06-03 Haiyan Jiang Method for the treatment of hemophilia
NZ594698A (en) * 2009-02-05 2013-08-30 Pierre Philippart Method and means for producing tissues and tissues obtained

Also Published As

Publication number Publication date
EP2244814B1 (en) 2021-06-02
BRPI0821474B1 (pt) 2021-03-30
NZ586383A (en) 2012-11-30
CN105816858A (zh) 2016-08-03
US20090192076A1 (en) 2009-07-30
US11191837B2 (en) 2021-12-07
KR101643277B1 (ko) 2016-07-28
ES2887187T3 (es) 2021-12-22
AU2008345135A1 (en) 2009-07-09
WO2009086400A2 (en) 2009-07-09
TWI515006B (zh) 2016-01-01
KR20100098693A (ko) 2010-09-08
TWI600437B (zh) 2017-10-01
CN105816858B (zh) 2024-10-18
CA2710762A1 (en) 2009-07-09
TW201438763A (zh) 2014-10-16
US20150216983A1 (en) 2015-08-06
BRPI0821474B8 (pt) 2021-05-25
TW201731488A (zh) 2017-09-16
SG187410A1 (en) 2013-02-28
JP5784907B2 (ja) 2015-09-24
EP2244814A2 (en) 2010-11-03
KR20160091434A (ko) 2016-08-02
EP3936116A1 (en) 2022-01-12
WO2009086400A3 (en) 2009-10-22
JP2016164199A (ja) 2016-09-08
AU2008345135C1 (en) 2015-04-30
AU2008345135B2 (en) 2014-02-13
JP2011508742A (ja) 2011-03-17
CN101952016A (zh) 2011-01-19
MX2010007150A (es) 2010-09-03
TW200940084A (en) 2009-10-01
JP2014159479A (ja) 2014-09-04
SG10201608059VA (en) 2016-11-29
AR069989A1 (es) 2010-03-03

Similar Documents

Publication Publication Date Title
BRPI0821474A2 (pt) formulação farmacêutica líquida estável
DK2346495T4 (da) Farmaceutisk formulering 514
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
LTPA2018005I1 (lt) Farmacinė kompozicija
DK2238985T4 (da) Højkoncentreret antistofholdig væskeformulering
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0721651A2 (pt) Composição farmacêutica
DE602007008562D1 (de) Flüssigkeitsausgabespritze
DK2114143T3 (da) Flydende sulfonylurea-herbicidformuleringer
SMT201400069B (it) Formulazione farmaceutica
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0908859A2 (pt) composição farmacêutica estabilizada de líquído único contedo docetaxel
PT2209464E (pt) Composição farmacêutica antimalárica
EP2306998A4 (en) PHARMACEUTICAL FORMULATION
IL203167A (en) Trazodone-based liquid pharmaceutical formulation
ATE480227T1 (de) Pharmazeutische zusammensetzungen mit quetiapinfumarat
BRPI0912656A2 (pt) formulação farmacêutica sólida
IL195034A0 (en) Liquid pharmaceutical formulation
EP2156832A4 (en) PHARMACEUTICAL COMPOSITION
BRPI0913709A2 (pt) "formulação farmacêutica"
BRPI0820839A2 (pt) Composição farmacêutica
BRPI1008983A2 (pt) formulação farmacêutica
FI20080123A0 (fi) Uusi farmaseuttinen formulaatio

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B25A Requested transfer of rights approved

Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)

B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)